Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
PaperCitations, authors & open-access status
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 1,212 citations, 2021 year and green oa status.
1,212
Citations
2021
Year
green
OA Status